# name
We know DAAs work, so now what? Simplifying models of care to                enhance the hepatitis C cascade

# metadata.dc.description.abstract[].value
Globally, some 71 million people are chronically
                infected with hepatitis C virus (HCV). Marginalised populations,
                particularly people who inject drugs (PWID), have low testing,
                linkage-to-care and treatment rates for HCV. Several models of
                care (MoCs) and service delivery interventions have the
                potential to improve outcomes across the HCV cascade of care,
                but much of the relevant research was carried out when
                interferon-based treatment was the standard of care. Often it
                was not practical to scale up these earlier models and
                interventions because the clinical care needs of patients taking
                interferon-based regimens imposed too much of a financial and
                human resource burden on health systems. Despite the adoption of
                highly effective, all-oral direct-acting antiviral (DAA)
                therapies in recent years, approaches to HCV testing and
                treatment have evolved slowly and often remain rooted in earlier
                paradigms. The effectiveness of DAAs allows for simpler
                approaches and has encouraged countries where the drugs are
                widely available to set their sights on the ambitious World
                Health Organization (WHO) HCV elimination targets. Since a large
                proportion of chronically HCV-infected people are not currently
                accessing treatment, there is an urgent need to identify and
                implement existing simplified MoCs that speak to specific
                populations' needs. This article aims to: 1) review the evidence
                on MoCs for HCV; and 2) distil the findings into recommendations
                for how stakeholders can simplify the path taken by chronically
                HCV-infected individuals from testing to cure and subsequent
                care and monitoring.

# metadata.dc.rights[].value
(c) The Association for the Publication of the Journal of Internal Medicine, 2019

# metadata.dc.source[].value
Articles publicats en revistes (ISGlobal)

# metadata.dc.title[].value
We know DAAs work, so now what? Simplifying models of care to                enhance the hepatitis C cascade